ProTransit Nanotherapy
Private Company
Funding information not available
Overview
ProTransit Nanotherapy is developing the Pro-MP™ platform, a nanotechnology-based sustained-release drug delivery system. The core innovation involves microparticles that can penetrate biological barriers and release therapeutics locally for up to 192 hours, aiming to improve efficacy while minimizing systemic side effects. Early data highlighted on its website suggests promising applications in cosmetic dermatology (reducing wrinkles, improving skin quality) and androgenetic alopecia (hair regrowth), with potential for broader therapeutic use. The company is a private, likely pre-revenue entity building on over a decade of academic research.
Technology Platform
Pro-MP™: A patented, sustained-release microparticle drug delivery platform designed to penetrate skin and tissues, releasing encapsulated active ingredients locally for up to 192 hours with minimal systemic uptake.
Opportunities
Risk Factors
Competitive Landscape
ProTransit competes in the drug delivery platform space with other nano/micro-particle companies and in specific indications with topical products from large pharma (e.g., Johnson & Johnson's Rogaine, Merck's Propecia) and aesthetic device/pharmaceutical firms (e.g., Allergan, Galderma). Its claimed efficacy advantages must be proven in head-to-head clinical trials.